Medicus Pharma has filed a clinical design with the United Arab Emirates Department of Health aimed at non-invasively treating Basal Cell Carcinoma (BCC), a type of skin cancer. The study is set to evaluate the effectiveness of two dose levels of D-MNA in comparison to a placebo control.

In the initial study, known as SKNJCT-001, the primary goal of assessing safety and tolerability was successfully met. The investigational product, D-MNA, showed good tolerance across all dose levels among the 13 participants involved, with no incidents of dose-limiting toxicities or serious adverse events reported.

Additionally, Medicus Pharma is currently conducting the SKNJCT-003 Phase 2 clinical study at nine clinical sites across the United States. The company anticipates completing an interim data analysis of this study by the end of the first quarter of 2025. Following this analysis, Medicus Pharma plans to submit its findings to the FDA as part of a request for a Type C meeting in the second quarter of 2025.